Abstract: Objective To study a retrospective analysis of the clinical effect of the neoadjuvant therapy of treating Her-2 positive breast cancer by applying Trastuzumab together with athracyclines and taxane-based chemotherapy.Methods 30 patients with Her-2 positive operable breast cancer were accepted 4 cycles ATH which were followed by 2~4 cycles TH regimen neoadjuvant chemotherapy before modified radical　mastectomy or conserving surgery.Then a statistical analysis was made.Results Among the 30 concerned patients,25(80%)reached completly remissio and Partial remission,and 15(50%)obtained pathological complete remission.Conclusion A complete pathological remission as well as a considerably high clinical benefit ratio can be achieved by treating Her-2 positive breast cancer with Trastuzumab together with athracyclines and taxane-based chemotherapy.Adverse reaction is tolerable.